AR117017A1 - DELIVERY CONSTRUCTS FOR TRANSCYTOSIS AND RELATED METHODS - Google Patents

DELIVERY CONSTRUCTS FOR TRANSCYTOSIS AND RELATED METHODS

Info

Publication number
AR117017A1
AR117017A1 ARP190103265A ARP190103265A AR117017A1 AR 117017 A1 AR117017 A1 AR 117017A1 AR P190103265 A ARP190103265 A AR P190103265A AR P190103265 A ARP190103265 A AR P190103265A AR 117017 A1 AR117017 A1 AR 117017A1
Authority
AR
Argentina
Prior art keywords
transcytosis
related methods
delivery constructs
methods
present
Prior art date
Application number
ARP190103265A
Other languages
Spanish (es)
Inventor
Weijun Feng
Tahir Mahmood
Randall J Mrsny
Charles Olson
Elbert Seto
Amir Porat
Original Assignee
Applied Molecular Transport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Molecular Transport Inc filed Critical Applied Molecular Transport Inc
Publication of AR117017A1 publication Critical patent/AR117017A1/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente provee moléculas de fusión que no existen en la naturaleza que comprenden porciones de carga terapéutica, tales como IL-22 con un vehículo. La presente también provee métodos y composiciones para la producción, purificación, plegado, formulación, y administración de moléculas de fusión. También se proveen métodos para usar las moléculas purificadas para tratar y prevenir enfermedades o trastornos.The present provides non-naturally occurring fusion molecules that comprise therapeutic cargo moieties, such as IL-22 with a carrier. The present also provides methods and compositions for the production, purification, folding, formulation, and administration of fusion molecules. Methods for using the purified molecules to treat and prevent diseases or disorders are also provided.

ARP190103265A 2018-11-07 2019-11-07 DELIVERY CONSTRUCTS FOR TRANSCYTOSIS AND RELATED METHODS AR117017A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862756889P 2018-11-07 2018-11-07

Publications (1)

Publication Number Publication Date
AR117017A1 true AR117017A1 (en) 2021-07-07

Family

ID=76160098

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP190102583A AR117643A1 (en) 2018-11-07 2019-09-11 CHOLIX-DERIVED VEHICLES FOR HETEROLOGICAL PAYLOAD ORAL DELIVERY
ARP190103265A AR117017A1 (en) 2018-11-07 2019-11-07 DELIVERY CONSTRUCTS FOR TRANSCYTOSIS AND RELATED METHODS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP190102583A AR117643A1 (en) 2018-11-07 2019-09-11 CHOLIX-DERIVED VEHICLES FOR HETEROLOGICAL PAYLOAD ORAL DELIVERY

Country Status (2)

Country Link
AR (2) AR117643A1 (en)
EA (1) EA202092126A1 (en)

Also Published As

Publication number Publication date
AR117643A1 (en) 2021-08-18
EA202092126A1 (en) 2021-05-24

Similar Documents

Publication Publication Date Title
CO2021007402A2 (en) Supply Constructs for Transcytosis and Related Methods
CL2018003153A1 (en) Antibody molecules for the treatment of cancer.
CL2018001089A1 (en) Valbenazine salts and polymorphs thereof.
CL2018003142A1 (en) Integrated stress path modulators
BR112019000528A2 (en) ve-mediated distribution of small molecule-binding protein conjugates
DOP2018000204A (en) NICOTINIC ACETILCOLINE RECEPTORS ALOSTERIC MODULATORS
CL2020000422A1 (en) Compositions of glp-1 and their uses.
PE20150201A1 (en) PROTEINS OF FIBROBLAST GROWTH FACTOR 21
CR20160222U (en) SOLID FORMS OF ACID {[- (3- CHLOROPHENYL) -3- HYDROXIPIRIDIN -2-CARBONIL] AMINO} ACETIC, COMPOSITIONS, AND USES OF THE SAME
MX365525B (en) TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES.
CL2019001512A1 (en) Treatment of neurological diseases.
MX2020004712A (en) Protein engineered extracellular vesicles.
CO2019002889A2 (en) Combination treatments comprising the administration of imidazopyrazinones
CL2021000207A1 (en) New fusion proteins specific for cd137 and pd-l1
BR112019001768A2 (en) spiro-lactam receptor modulators and their uses
CL2019001891A1 (en) Bicyclic bis-heteroaryl derivatives as protein aggregation modulators.
CL2020001495A1 (en) Compositions and method for the treatment of metabolic diseases
BR112018067946A2 (en) topical formulations containing cyclosporine and their uses
DOP2019000112A (en) PIRIDO [3,4-b] SUBSTITUTE INDOLES FOR TREATMENT OF DISORDERS OF CARTILAGE
PH12021550872A1 (en) Therapeutic compounds
BR112017012581A2 (en) retinal degeneration treatment using progenitor cells
CO2021013171A2 (en) Compounds and compositions as modulators of tlr signaling
CR20230177A (en) Compounds and compositions as modulators of tlr signaling
MX2020009566A (en) Compounds as modulators of tlr2 signaling.
MX2016006544A (en) Withanolides useful for the treatment of neurodegenerative diseases.